The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis

Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options

“…ACE2 converts AngII to Ang (1–7), which increases NO release and has an anti-inflammatory and anticoagulant role. BRACECORONA was the first randomized controlled trial that showed that discontinuation of RAAS inhibitors in COVID-19 did not ameliorate mortality risk [ 158 ]. A cohort study including 8.3 million people [ 159 ] showed that RAAS inhibitors reduce the risk of COVID-19; susceptibility could be associated with the ethnic-specific effects of this drug class.…”

Different death rates between COVID-19 waves among unvaccinated patients: moving beyond lessons learned

“…Fourth, introduction of more effective treatment schemes for COVID-19 has certainly played a major role in improving patients’ survival between waves, in particular early use of systemic steroids and high-dose low-molecular-weight heparin (LMWH) [ 11 , 12 ]. Thanks to autopsy studies, we gained a better understand of COVID pathophysiology and the key role of the massive inflammatory response (the so-called “cytokine storm”) triggered by SARS-CoV-2 [ 13 ].…”

Efficient dispersive solid-phase extraction of methylprednisolone from exhaled breath of COVID-19 patients

“… 1 In the treatment of COVID-19 patients, a low dose of methylprednisolone was reported to have lower short-term mortality and less need for intensive care unit (ICU) admission and mechanical ventilation, and increased 28 days ventilator-free days without increasing the risk of secondary infections, but it may slightly prolong the duration of viral shedding. 2 Therefore, monitoring its concentration in the biological samples will be critical for therapeutic drug monitoring purposes.…”